These CGM data support the long-term efficacy and safety of icodec versus glargine U100 during treatment and indicated no increase in the duration of individual hypoglycaemic episodes with icodec versus glargine U100 in insulin-naive individuals with type 2 diabetes.
We are excited to announce that the ERP DSMES Symposium and the Medicare Reimbursement symposium are now available on-demand until December 31, 2024. Both symposiums…
SAN ANTONIO — Access to GLP-1 medications is potentially impacted by care site, payer type and demographics, highlighting gaps in care that disproportionately affect certain…
Advocates for action on rare diseases are having a moment. Oct 28 saw the launch of the European Rare Diseases Research Alliance, an ambitious initiative…
SAN ANTONIO — Half of adolescents had two or more micronutrient deficiencies 10 years after metabolic and bariatric surgery, with deficiencies more common after Roux-en-Y…
The Best of ObesityWeek® | Your selection of highlights and key takeaways from ObesityWeek®.
Respiratory syncytial virus vaccination was effective in preventing respiratory syncytial virus-associated hospitalisations and emergency department encounters among adults aged at least 60 years in the…
The Best of ObesityWeek® | Your selection of highlights and key takeaways from ObesityWeek®.
This initiative is designed to help primary care clinicians establish practice-level strategies for enhancing patient-centered care of diabetes with diabetes technology. The educational strategies learned…
